arrow
R

Romain Marlin

Universite de Bordeaux
H指数:20
被引数:1,758

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

OVX033 nucleocapsid vaccine induces cross-reactive T cells and boosts memory in SARS-CoV-2-primed non-human primates

OVX033核衣壳疫苗诱导交叉反应性T细胞并增强SARS-CoV-2预免疫非人灵长类动物的记忆

2026-09-220
OAAI
Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection
2026-07-310
OAAI
Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing

法匹拉韦的组织分布和抑制倍数在临床前模型中:迈向循证抗病毒药物重定位的流程

2026-07-030
OAAI
Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates

非人灵长类中无佐剂CD40靶向SARS-CoV-2疫苗的免疫原性和保护效力

2026-07-010
OA
Exposure history shapes SARS-CoV-2 viral dynamics in non-human primates and provides insights into correlates of protection against infection and transmission

暴露史塑造非人灵长类动物中SARS-CoV-2病毒动力学,并提供了关于感染和传播保护性关联的见解

2026-04-300
PRE
Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques
2024-04-031
OA
A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
2024-03-015
OAAI
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys
2023-12-012
OA
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection

嘌呤能受体P2X7和NLRP3炎性体是SARS-CoV-2感染所需的可药物宿主因子

2023-10-187
OAAI
Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses
2023-09-0723
PRE
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
2022-08-3020
OAAI
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
2022-07-089
OA
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

用合成SARS-CoV-2 S糖蛋白病毒样颗粒预防接种保护猕猴免受感染

2022-02-015
OAAI
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
2021-10-2033
OAAI
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
2021-09-0125
OAAI